Gil Chernin - Publications

Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: November 06, 2025

Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses.

Journal: Journal of the American College of Cardiology

Published: September 26, 2025

Impact of polygenic risk score (PRS) for coronary artery disease on physician decision-making and patient care.

Journal: Frontiers in genetics

Published: May 09, 2025

Advanced machine learning techniques for coronary artery disease risk prediction in early middle-aged adults.

Journal: BMC medical genomics

Published: December 13, 2024

Multiethnic prevalence of the APOL1 G1 and G2 variants among the Israeli dialysis population.

Journal: Clinical kidney journal

Published: October 08, 2024

Harnessing the eccrine sweat glands for the management of interdialytic weight gain - a pilot study.

Journal: Renal failure

Published: September 23, 2024

Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.

Journal: European heart journal

Published: July 01, 2024

Inside CKD: Cost-Effectiveness of Multinational Screening for CKD.

Journal: Kidney international reports

Published: May 14, 2024

Delivering Dialysis during Wartime: The Israeli Experience.

Journal: Kidney360

Published: February 06, 2024

Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis.

Journal: Journal of medical economics

Published: October 09, 2023

Percutaneous coronary intervention with ridaforolimus-eluting stents in long lesions: the BIONICS 38 mm prospective trial.

Journal: Coronary artery disease

Published: July 20, 2023

Control of diabetes mellitus and the risk of neointimal hyperplasia after percutaneous coronary intervention: Post-hoc analysis from the BLADE-PCI trial.

Journal: Atherosclerosis

Published: February 06, 2023